The published literature describes BPC-157 as unusually stable for a peptide of its length, with the high proline content (five of fifteen residues) and absence of cysteine bridges cited as contributing factors
Why GHK-Cu Dosage Depends on the Administration Route GHK-Cu dosing differs fundamentally between systemic injectable research and topical research
This GHR upregulation sensitises local cells to circulating GH, potentiating GH-induced JAK2/STAT signalling and stimulating collagen matrix synthesis, IGF-1 production, and fibroblast proliferation providing a mechanism through which BPC-157 engages the GH/IGF-1 axis at the tissue level without altering systemic GH secretion
A., Lee, Y., Kim, J., Han, C., Kim, H
Argelles, J
BPC-157 is typically dosed twice daily